Tardive Dyskinesia Market Overview

The global Tardive Dyskinesia market is estimated to be worth over USD 8.74 Bn in 2033 and is expected to grow at CAGR of 9.3% during the forecast period (2024-2033).

Tardive dyskinesia (TD) can be understood as a neurological disorder marked by involuntary, repetitive movements of the tongue, face, lips, and extremities, time and again, resulting from prolonged exposure to certain medications, particularly antipsychotic drugs used to treat psychiatric conditions such as bipolar disorderand schizophrenia. Tardive dyskinesia presents a substantialstrain on affected individuals, influencing their quality of life and social functioning. The global market for tardive dyskinesia surrounds a scale of diagnostic, treatment, and supportive care interventions emphasized at administering symptoms and enhancing patient outcomes. Diagnosis of tardive dyskinesia usuallyincludes clinical evaluation and evaluation of movement abnormalities, oftentimesassisted by standardized rating scales. Treatment alternatives for TD comprise discontinuation or dose reduction of offending medications, though this approach is not likely to always be feasible owing to the underlying psychiatric condition requiring treatment.

Other pharmacological interventions, such as vesicular monoamine transporter 2 (VMAT2) inhibitors, have shown efficiency in mitigating TD symptoms by modulating dopamine levels in the brain. In addition to that, supportive therapies such as speech therapy and occupational therapy are likely to help individuals cope with TD-associated impairments and enhance their functional abilities. The global market for TD is marked by continuing research and development efforts focused at advancing understanding of the disorder's underlying mechanisms and determining novel therapeutic targets. Emerging trends in the TD market include the development of next-generation VMAT2 inhibitors with improved efficacy and tolerability profiles, as well as the exploration of non-pharmacological interventions such as deep brain stimulation. Regardless of these advancements, challenges continue, comprising underdiagnosis of TD, limited treatment alternatives, and the need for better management strategies tailored to individual patient necessities. However, with sustained investment in research, innovation, and collaborative efforts across healthcare sectors, the global market for tardive dyskinesia holds commitment for enhanced diagnosis, treatment, and quality of life for individuals affected by this debilitating neurological disorder.

Figure 1. Tardive Dyskinesia: Market Size

Get more details on this report - Request Free Sample

Key Market Insights &Current Market Landscape:

The global tardive dyskinesia (TD) market is marked by key insights into a complicatedpanoramadefined by neurological disorders and psychiatric treatments. Significant developments in the market comprise advancements in diagnostic techniques, such as standardized rating scales and clinical assessments, supporting accurate identification and characterization of TD symptoms. Treatment alternatives for TD have expanded in the past few years, with the emergence of vesicular monoamine transporter 2 (VMAT2) inhibitors, which have reflectedefficiency in mitigating involuntary movements related to TD. These novel pharmacological interventions represent a substantial advancement in the management of TD, providing patients relief from debilitating symptoms and enhancing their quality of life. In addition to that, emerging technologies such as deep brain stimulation and non-invasive brain stimulation techniques hold hope for future therapeutic interventions in TD. Notwithstanding with these advancements, challenges continue in the TD market, comprising underdiagnosis, limited awareness among healthcare professionals, and the necessity for better management strategies tailored to individual patient needs. However, with ongoing research, innovation, and collaborative efforts, the global TD market stands ready for further growth and enhancement in patient care and outcomes.

Market Dynamics

Market Drivers

Rise in the Prevalence of Psychotic or Neurological Disorders

Psychotic disorders, such as bipolar disorders and schizophrenia, oftentimesneed long-term treatment with antipsychotic medications, which are known to be a chief risk factor for TD development. As the incidence and prevalence of these psychiatric conditions increase across the worldowing to factors such as population growth, aging demographics, and enhanced diagnosis and recognition, there is a corresponding surge in the number of individuals at risk of developing TD. In addition to that, neurological disorders such as Parkinson's disease, which also need treatment with dopamine-modulating medications, further contribute to the pool of individuals susceptible to TD. This soaring patient population highlights the pressing need for effective management strategies and therapeutic interventions to address TD-related symptoms and enhance patient outcomes. Consequently, the expanding prevalence of psychotic and neurological disorders drives demand for diagnostic tools, treatment alternatives, and supportive care interventions in the global TD market, creating opportunities for growth and innovation in this complex neurological disorder outlook.

Market Restraints

With regard to numerous advantages of Tardive Dyskinesia, the market faces several challenges due to the unique characteristics and requirements associated with them. Some of the key market challenges include:

• Limited Awareness and Underdiagnosis: A substantial market restraint for the global tardive dyskinesia market is the inadequacy of awareness among healthcare professionals and patients, resulting in underdiagnosis and delayed treatment initiation.
• Adverse Effects of Current Treatments: Existing pharmacological interventions for tardive dyskinesia, such as vesicular monoamine transporter 2 (VMAT2) inhibitors, are estimated to be associated with adverse effects or limited efficacy, offering challenges in treatment adherence and patient management.

Market Opportunities

Increase in the Demand for Disease-Specific Novel Treatment

Since awareness of TD grows among healthcare professionals and patients, there is an escalated demand for effective and targeted therapeutic interventions to address the debilitating symptoms related to this neurological disorder. This rise in demand creates opportunities for pharmaceutical companies and biotechnology companies to invest in research and development efforts focused at developing innovative treatments particularly personalized to TD. Novel therapies, such as vesicular monoamine transporter 2 (VMAT2) inhibitors, which have shown promise in reducing TD symptoms, represent a step towards meeting this demand for disease-specific treatments. In addition to that, advancements in precision medicine approaches and biomarker-driven therapies offer potential avenues for personalized treatment strategies, further catering to the varied needs of TD patients. By capitalizing on the growing demand for disease-specific novel treatments, stakeholders in the global TD market can address unmet medical needs, improve patient outcomes, and differentiate their products in an increasingly competitive panorama, ultimately fueling growth and innovation in the domain of neurological disorders.

Market Trends

• Increasing Focus on Precision Medicine: There is a prominent trend towards the adoption of precision medicine approaches in the global tardive dyskinesia market, leveraging advancements in molecular profiling and biomarker testing to personalize treatment regimens to individual patient characteristics and disease profiles.
• Expansion of Non-pharmacological Interventions: There is a significant trend towards the development and adoption of non-pharmacological interventions in the treatment of tardive dyskinesia, including deep brain stimulation and non-invasive brain stimulation techniques, offering potential alternatives or adjuncts to traditional pharmacotherapy for administering TD symptoms.

Get more details on this report - Request Free Sample

Tardive Dyskinesia Market: Key Segments

By Treatment

• Medication
• Surgery

By Drugs

• Approved Drugs
• Off-label Drugs

By Route of Administration

• Oral
• Injectable

By End- Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America 

Tardive Dyskinesia Market: Regional Analysis

North America dominates the tardive dyskinesia treatment market due to the rise in the incidence of schizophrenia. Furthermore, the growth of the health alertness and the increase in the research and development investment will further boost the growth of the tardive dyskinesia treatment market in the region during the forecast period. Asia-Pacific is projected to observe a significant amount of growth in the tardive dyskinesia treatment market due to a rise in health awareness. Moreover, the increase in the number of schizophrenic, bipolar, and other neuroleptic disorder patients is further anticipated to propel the growth of the tardive dyskinesia treatment market in the region in the coming years.

Figure 4. Tardive Dyskinesia Market: Distribution by Region

Get more details on this report - Request Free Sample

Leading Tardive Dyskinesia Developers

Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities associated with the Tardive Dyskinesiamarket, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the biopharmaceutical industry. Key takeaways of the Tardive Dyskinesiamarket are briefly discussed below. 

The report includes the list of players operating in the global Tardive Dyskinesiamarket. Some of the key players include: 

• Amgen Inc  
• AbbVie Inc
• Bionpharma
• Bausch Health
• Bayer AG
• Baxter
• Dr. Reddy’s Laboratories Ltd
• GlaxoSmithKline Plc.
• Hetero
• Johnson & Johnson Services, Inc.
• Lupin Pharmaceuticals Inc.
• Lilly
• Merck KGaA
• Medicure Inc
• Novartis AG
• Neurocrine Biosciences, Inc
• Mylan N.V
• Pfizer Inc
• Sun Pharmaceutical Industries Ltd
• Sanofi
• Teva Pharmaceutical Industries Ltd

Recent Developments in the Tardive Dyskinesia Market

Several recent developments have taken place in the field of Tardive Dyskinesia, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we’ve outlined in our analysis chronologically.

• In June 2022, Mitsubishi Tanabe Pharma Corporation, a member of the Mitsubishi Chemical Holdings Group, announced that MTPC is launching DYSVAL^® capsules 40mg (generic name: valbenazine, DYSVAL) (the vesicular monoamine transporter type 2 (VMAT2) inhibitor) for the treatment of tardive dyskinesia in Japan following the inclusion of DYSVAL in the NHI drug price listing on May 25,2022.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments, as defined in the below table: